Clinical Trial Update: A Placebo Controlled, Double Blind, Randomised, 8-week Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of AKR 202 in Patients With Osteoarthritis Pain [Phase 2]

View source ↗

Summary

A Phase IIa randomized, double-blind, placebo-controlled study assessing the efficacy and safety of AKR 202 in patients with osteoarthritis pain has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis

Drugs mentioned

• AKR 202

Snippet

Sponsor: Akron Molecules AG | Conditions: Osteoarthritis | Phase 2 | Status: COMPLETED